Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

US11311522B1 · kind B1 · utility

Assignee

• Cavion, Inc. · US

Inventors

• Margaret Lee · Middleton, US
• Spyridon Papapetropoulos · Wellesley, US
• Michelle Higgin · Holly Springs, US
• Muralikrishna Duvvuri · Chapel Hill, US
• Bruce Rehlaender · Chapel Hill, US
• Evan Newbold · Charlottesville, US

Key dates

• Filing date: May 6, 2021
• Grant date: Apr 26, 2022
• Expiry date: May 6, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.